Document is current
Any future updates will be listed below
-
Authors
Jia, Xinyuan
Jiang, Hanyu
Ye, Zheng
Wei, Hong
Chen, Jie
Qu, Yali
Sirlin, Claude B.
Song, Bin https://orcid.org/0000-0002-7269-2101
Wang, Yanshu
-
Funding
Funding for this research was provided by:
Sichuan Science and Technology Program (2024ZDZX0017)
National Natural Science Foundation of China (82471960)
National Natural Science Foundation of China (U22A20343)
National Natural Science Foundation of China (82202111)
National Natural Science Foundation of China (82302161)
Natural Science Foundation of Sichuan Province (2024NSFSC1798)
Natural Science Foundation of Sichuan Province (2024NSFSC1799)
Science and Technology Department of Hainan Province (ZDYF2024SHFZ052)
Development Project of Hainan Provincial Clinical Medical Center and Postdoctoral Station Development Project of Sanya (23CZ009)
Postdoctoral Research Fund of West China Hospital, Sichuan University (2024HXBH161)
- License Information
-
More Information
Article History
Received: 17 July 2025
Revised: 5 September 2025
Accepted: 29 September 2025
First Online: 30 October 2025
Compliance with ethical standards
:
: The scientific guarantor of this publication is Bin Song.
: The authors of this manuscript declare relationships with the following companies: Hanyu Jiang is a stock owner of Kanghong Technology Co., Ltd. Claude B. Sirlin reports payment to the institution for research grants from ACR, Bayer, Foundation of NIH, GE, Gilead, Pfizer, Philips, Siemens, and V Foundation. Payment to institution for lab service agreements with OrsoBio, Enanta, Gilead, ICON, Intercept, Nusirt, Shire, Synageva, and Takeda. Payment to the institution for institutional consulting for BMS, Exact Sciences, IBM-Watson, and Pfizer. Personal consulting for Altimmune, Ascelia Pharma, Blade, Boehringer, Epigenomics, Guerbet, Livivos, and Novo Nordisk. Payment to self for royalties and/or honoraria from Medscape, Wolters Kluwer, and HealthProMatch. Ownership of stock options in Livivos; unpaid advisory board position in Quantix Bio; executive position for Livivos (Chief Medical Officer, unsalaried position with stock options and stock) through June 28, 2023; and principal Scientific Advisor to Livivos (unsalaried position with stock options and stock) since June 28, 2023. Payment to self for serving as a speaker for HealthProMatch; support for attending meetings and/or travel from Fundacion Santa Fe, Congreso Argentino de Diagnóstico por Imágenes, Stanford, Jornada Paulista de Radiologia, Ascelia Pharma, RSNA, Sociedad Radiológica de Puerto Rico, Hospital Español Auxilio Mutuo de Puerto Rico, Paris MASH, Liver Forum, University of Cincinnati, University of Mississippi. Member (no payment) of the Data Safety Monitoring Board for the National Cancer Institute-funded Early Detection Research Network. Equipment loans to the institution from Butterfly, GE, Siemens, and Mayo. Provision of contrast material to the institution from Bayer.
: No complex statistical methods were necessary for this paper.
: Written informed consent was not required for this study because this is a Review article.
: Institutional Review Board approval was not required because this is a Review article.
: None.
:
